title: Common links between metabolic syndrome and inflammatory bowel disease: Current overview and future perspectives.
abstract: Metabolic syndrome (MS) features a constellation of central obesity, dyslipidemia, impaired glucose metabolism and often hypertension joined by insulin resistance and chronic inflammation. All these elements greatly raise patient's risk of cardiovascular disease and type 2 diabetes, resulting in an increased mortality. Metabolic syndrome affects approximately 20-25% of the world's adult population and thus it is essential to study its pathophysiology and seek new pharmacological targets. There is a thoroughly studied link between MS and inflammatory diseases of the gastrointestinal (GI) system, i.e. steatohepatitis. However, recent findings also indicate similarities in pathophysiological features between MS and inflammatory bowel disease (IBD), including adipose tissue dysregulation, inadequate immune response, and inflammation. In this review we aim to outline the pathophysiology of MS and emphasize the aspects revealed recently, such as mineralocorticoid activity, involvement of sex hormones and an accompanying increase in prolactin secretion. More importantly, we focus on the common links between MS and IBD. Finally, we describe new strategies and drug targets that may be utilized in MS therapy, namely adiponectin mimetics, GLP-1-based multi agonists, ABCA1 agonists and possible role of miRNA. We also discuss the possible utility of selected agents as adjuvants in IBD therapy.
authors.affiliation: Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Łódź, Poland.
authors.forename: Arkadiusz
authors.initials: A
authors.lastname: Michalak
authors.affiliation: Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Łódź, Poland.
authors.forename: Paula
authors.initials: P
authors.lastname: Mosińska
authors.affiliation: Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Łódź, Poland. Electronic address: jakub.fichna@umed.lodz.pl.
authors.forename: Jakub
authors.initials: J
authors.lastname: Fichna
mesh_terms: D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000503:physiopathology*; D024821:Metabolic Syndrome / Q000188:drug therapy* / Q000503:physiopathology*; D058990:Molecular Targeted Therapy / Q000379:methods*
keywords: Adipokines; Glucagon-like-peptide 1; Inflammatory bowel disease; Metabolic syndrome; microRNA